FDA accepts Aimmune's peanut allergy therapy for review

Aimmune said the recent government shutdown may add about a month onto the approval timeline for its peanut allergy therapy. On Monday, FDA accepted for review a BLA for AR101 to treat peanut

Read the full 332 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE